NCT01929941: An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies |
|
|
| Terminated | 1 | 5 | US | INCB047986, Gemcitabine, Gemzar®, nab-paclitaxel, Abraxane® | Incyte Corporation | Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer | 08/14 | 08/14 | | |
